Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189)

HKG:8189 Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 12, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	971	616	169	379	322	186
Market Cap Growth	245.75%	265.17%	-55.50%	17.65%	73.47%	-20.97%
Enterprise Value	1,123	945	219	415	295	151
Last Close Price	0.46	0.33	0.09	0.20	0.17	0.10
PS Ratio	2.37	1.50	0.39	0.83	0.55	0.42
PB Ratio	32.08	20.34	2.37	4.13	2.38	1.01
P/TBV Ratio	41.19	26.12	3.06	5.78	2.60	1.11
P/FCF Ratio	-	-	-	-	-	5.23
P/OCF Ratio	-	-	-	-	-	4.34
EV/Sales Ratio	2.74	2.30	0.50	0.91	0.51	0.34
EV/FCF Ratio	-36.61	-	-	-	-	4.26
Debt / Equity Ratio	5.70	5.70	1.33	1.26	0.82	0.35
Debt / FCF Ratio	-	-	-	-	-	1.83
Asset Turnover	1.21	1.21	1.24	1.18	1.29	0.98
Inventory Turnover	4.45	4.45	4.58	5.21	5.16	3.64
Quick Ratio	0.14	0.14	0.11	0.21	0.35	0.45
Current Ratio	0.84	0.84	0.88	0.89	1.09	1.34
Return on Equity (ROE)	-81.67%	-81.67%	-15.05%	-24.59%	-33.73%	-27.93%
Return on Assets (ROA)	-5.58%	-5.58%	-3.77%	-4.46%	-3.10%	-4.23%
Return on Capital (ROIC)	-10.41%	-10.41%	-7.23%	-7.94%	-5.60%	-7.06%
Earnings Yield	-3.05%	-4.81%	-13.17%	-8.19%	-16.11%	-30.70%
FCF Yield	-3.16%	-4.98%	-10.21%	-6.45%	-13.07%	19.11%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.